Abstracts P063

VERIFY: A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera

Verstovek Srdan , Kuykendall Andrew T , Hoffman Ronald , Koschmieder Steffen , Passamonti Francesco , Valone Frank , Modi Nishit B , Khanna Sarita , O‚ÄôConnor Paula G , Gupta Suneel K. and Kiladjian Jean-Jacques
University of Texas MD Anderson Cancer Center, Houston, Texas, USA; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA; Tisch Cancer Institute, Icahn School of Medicine At Mount Sinai Medical Center, New York, New York, USA; RWTH Aachen University, Aachen, Germany; University of Insubria, Varese VA, Italy; Protagonist Therapeutics, Newark, California, USA; Universit√© de Paris, INSERM, H√¥pital Saint-Louis, Paris, France

Presented at Lymphoma, Leukemia, and Myeloma 2022

Introduction:
Patients with polycythemia vera (PV) are treated with periodic therapeutic phlebotomy (TP) alone or in combination with cytoreductive therapies (CRT) to maintain hematocrit (HCT) 45%, thereby increasing their risk of thrombosis [Marchioli NEJM 2013]. Indeed, a study of more than 4,000 US patients with PV in 2018 and 2019 found that only 22% maintained HCT
The study is comprised of three parts:

Part 1a: 1:1 randomized, double-blind, placebo-controlled, add-on phase with parallel-groups lasting 32‚Äâweeks.
Methods:
VERIFY (NCT05210790) is a phase 3, multicenter, global, randomized trial comparing the efficacy and safety of rusfertide versus placebo when added to ongoing therapy for PV (ie, TP alone or with concurrent CRT)

Publisher

John Wiley & Sons; Hoboken, USA

Source Journal

American Journal of Hematology

E ISSN 1096-8652 ISSN 0361-8609

2022 Wiley Periodicals LLC.

Recent News

Conference Coverage

Berlrestotug Added to Dostarlimab Demonstrates Antitumor Activity in PD-L1-High Locally Advanced or Metastatic Non-Small Cell Lung Cancer

09/16/2024

Stephanie Holland ;

Results from the phase 2 GALAXIES Lung-201 study show the addition of berlrestotug to dostarlimab demonstrates antitumor activity among patients with PD-L1-high locally advanced or metastatic non-small cell lung cancer.

Results from the phase 2...

09/16/2024

Oncology

FDA Approval

FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors

09/13/2024

Stephanie Holland ;

On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...

On September 12th, 2024, the US...

09/13/2024

Oncology

Conference Coverage

Datopotamab Deruxtecan Shows Promise for Unresectable Advanced Endometrial and Ovarian Cancers

09/12/2024

Allison Casey ;

According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.

According to results of the...

09/12/2024

Oncology

News

Sacituzumab Govitecan Shows Potential Among Patients With Locally Advanced or Metastatic Urothelial Cancer

09/10/2024

Stephanie Holland ;

According to results from Cohort 2 of the phase 2 TROPHY-U-01 trial, sacituzumab govitecan demonstrated clinically meaningful antitumor activity among patients with locally advanced or metastatic urothelial cancer who are cisplatin-ineligible...

According to results from Cohort...

09/10/2024

Oncology

Conference Coverage

Biomarkers With Alectinib for ALK-Positive Non-Small Cell Lung Cancer

09/10/2024

Allison Casey ;

According to exploratory biomarker analyses from the phase 3 ALINA trial, there was a benefit to disease-free survival with alectinib regardless of EML4-ALK variant among patients with NSCLC.

According to exploratory...

09/10/2024

Oncology

Conference Coverage

Inhaled Corticosteroids to Reduce Radiation-Induced Pneumonitis Among Patients With Non-Small Cell Lung Cancer

09/10/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that the addition of inhaled corticosteroids with radiotherapy significantly reduced the incidence of radiation-induced pneumonitis among patients with non-small cell lung cancer.

Results from a phase 2 study...

09/10/2024

Oncology

Conference Coverage

Neoadjuvant Nivolumab Demonstrated Promising Efficacy and Safety Among Patients With High-Risk Early Non-Small Cell Lung Cancer

09/10/2024

Stephanie Holland ;

According to results from the phase 2 POTENTIAL study, neoadjuvant nivolumab demonstrated efficacy and safety among patients with stage I non-small cell lung cancer, at high-risk of recurrence.

According to results from the...

09/10/2024

Oncology

Conference Coverage

Zipalertinib Demonstrated Promising Anti-Tumor Activity Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer

09/10/2024

Stephanie Holland ;

According to results from the phase 2b REZILIENT1 study, zipalertinib demonstrated promising anti-tumor activity among patients with EGFR exon 20 insertion-mutated non-small cell lung cancer who experienced disease progression after treatment...

According to results from the...

09/10/2024

Oncology

Conference Coverage

Ivonescimab As New First-Line Treatment Option for Patients with PD-L1–Positive, Advanced Non-Small Cell Lung Cancer

09/09/2024

Allison Casey ;

Ivonescimab showed a clinically meaningful and statistically significant improvement to progression-free survival for patients with PD-L1–positive, advanced non-small cell lung cancer, when compared with pembrolizumab.

Ivonescimab showed a clinically...

09/09/2024

Oncology

Conference Coverage

Tifcemalimab Plus Toripalimab Demonstrated Promising Antitumor Activity For Refractory Extensive-Stage Small Cell Lung Cancer

09/09/2024

Stephanie Holland ;

According to phase 1/2 study results, tifcemalimab plus toripalimab showed promising antitumor activity with a manageable safety profile among patients with refractory extensive-stage small cell lung cancer.

According to phase 1/2 study...

09/09/2024

Oncology